PRFX

PRF Technologies Ltd

0.7868

Nov 12 • 4:00 PM ET +0.0433 (5.82%)

0.8200

Aftermarket • 7:44 PM ET +0.0332 (4.22%)

Healthcare Drug Manufacturers - Specialty & Generic Israel Nano NASD

Nov 12, 4:11 PMPRF Technologies says Nasdaq issued a delisting determination over its minimum bid-price rule

Peers: PCRX TLPH HROW RDHL AQST EYPT OCUL SNOA STEM TGEN

Scroll to Statements

Index	-
Market Cap	2.39M
Enterprise Value	-8.52M
Income	-5.32M
Sales	0.03M
Book/sh	5.22
Cash/sh	3.81
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	7
IPO	Sep 01, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	79.67
P/B	0.15
P/C	0.21
P/FCF	-
EV/EBITDA	-
EV/Sales	-284.00
Quick Ratio	5.07
Current Ratio	5.07
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-5.28
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	80.39% 55.23%
Sales past 3/5Y	- -
EPS Y/Y TTM	99.47%
Sales Y/Y TTM	-
EPS Q/Q	-3.64%
Sales Q/Q	-
Earnings	Sep 03 BMO
EPS/Sales Surpr.	-5.77% -

Insider Own	0.00%
Insider Trans	-
Inst Own	12.93%
Inst Trans	0.19%
ROA	-35.16%
ROE	-43.75%
ROIC	-33.51%
Gross Margin	-3716.13%
Oper. Margin	-16629.03%
Profit Margin	-17158.06%
SMA20	3.56%
SMA50	-8.40%
SMA200	-52.86%
Trades

Shs Outstand	0.03M
Shs Float	-
Short Float	-
Short Ratio	0.04
Short Interest	0.01M
52W High	7.95 -90.10%
52W Low	0.64 22.75%
Volatility	15.83% 10.78%
ATR (14)	0.08
RSI (14)	48.46
Beta	1.13
Rel Volume	0.88
Avg Volume	312.04K
Volume	273,369

Perf Week	3.69%
Perf Month	-3.91%
Perf Quarter	-23.61%
Perf Half Y	-50.20%
Perf YTD	-75.48%
Perf Year	-83.76%
Perf 3Y	-99.67%
Perf 5Y	-99.97%
Perf 10Y	-
Recom	1.00
Target Price	240.00
Prev Close	0.74
Price	0.79
Change %	5.82%

Nov-12-26 04:05PM	PRF Technologies Receives Nasdaq Delisting Determination Regarding Minimum Bid Price Requirement and Requests a Hearing (GlobeNewswire) +5.82%
Nov-03-26 04:05PM	PRF Technologies and Dotz Nano Sign Term Sheet for Strategic Collaboration to Expand AI-Driven Energy Optimization Offering (GlobeNewswire) -5.20% +7.59%
Oct-23-26 09:06AM	PRF Technologies Issues Letter to Shareholders Highlighting $11.0 Million Cash Position, Entering Phase 2 Trial of OcuRing-K and GridFeed Opportunity in AI Data Center Power (GlobeNewswire)
Sep-16-26 09:00AM	PRF Technologies' GridFeed(TM) to Explore Strategic Growth Opportunity in AI Data Center Power Optimization (GlobeNewswire) +12.22%
Sep-09-26 08:30AM	PRF Technologies to Establish GridFeed as a Standalone Subsidiary to Pursue Strategic Alliances for Its AI-Driven Renewable Energy Trading Platform (GlobeNewswire)
08:30AM	Loading…
Sep-03-26 08:30AM	PRF Technologies Provides First Half 2026 Business Update Highlighting Significant Progress Across Healthcare and AI Energy Business (GlobeNewswire)
Jul-27-26 08:30AM	PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms (GlobeNewswire)
Jul-21-26 08:30AM	PRF Technologies to Showcase GridFeed at Energy Trading Week Europe 2026 (GlobeNewswire)
Jul-15-26 09:15AM	PRF Technologies Expands DeepSolar Predict Platform with Battery-to-Revenue Intelligence, Extending AI-Driven Revenue Optimization Across Solar and Energy Storage Assets (GlobeNewswire)
Jul-08-26 08:30AM	PRF Technologies' DeepSolar Successfully Validates Predict AI Platform for Renewable Energy Revenue Optimization Using Real-World European Market Data (GlobeNewswire) -5.22%
Jun-25-26 08:30AM	PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark (GlobeNewswire) +13.48%
May-28-26 08:30AM	PRF Technologies Advances DeepSolar Predict Toward Commercial Launch as AI Platform Targets Revenue Optimization Across Renewable Energy Markets (GlobeNewswire)
May-26-26 08:30AM	PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study (GlobeNewswire) -10.07%
Apr-28-26 08:00AM	PRF Technologies Announces FDA Clearance of IND Application for OcuRing-K Phase II Clinical Trial (GlobeNewswire) -10.92%
Apr-06-26 10:30AM	BC-Most Active Stocks (Associated Press) +20.48%
08:00AM	Loading…
Mar-27-26 08:00AM	PRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms (GlobeNewswire) -11.86%
Mar-17-26 08:30AM	PRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial Engagements (GlobeNewswire) -6.20%
Feb-18-26 09:15AM	PRF Technologies' DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable Energy (GlobeNewswire)
Feb-11-26 08:30AM	PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial Base (GlobeNewswire) +8.47%
Jan-20-26 09:05AM	PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy (GlobeNewswire) -13.54%
Jan-16-26 11:39AM	PainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy Push (Benzinga) +37.96%
Jan-15-26 04:05PM	PainReform Ltd. Changes Name to PRF Technologies Ltd. Reflecting Expansion into Diversified Healthcare and AI-Driven Energy Platforms (GlobeNewswire)
Jan-12-26 09:00AM	PainReform's LayerBio's Drop-Less OcuRing-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies (GlobeNewswire) -5.55%
Jan-05-26 09:00AM	PainReform's DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market (GlobeNewswire)
Dec-30-25 08:48AM	BladeRanger to Showcase Advanced Green Energy Technologies at Abu Dhabi Sustainability Week (PR Newswire) -6.98%
Dec-10-25 08:30AM	PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities (GlobeNewswire)
Dec-02-25 09:15AM	PainReform Commences Development for OcuRing-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular Therapy (GlobeNewswire)
Nov-12-25 09:00AM	PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis (GlobeNewswire) +9.26%
Nov-05-25 08:30AM	PainReform's DeepSolar, Developing "DeepSolar Predict" within the NVIDIA Connect Program, Featured in The Market Link's "Watchlist Interview" and Announces Progress Toward Pilot Projects (GlobeNewswire) +6.67%
Oct-01-25 09:27AM	PainReform Provides Business Update for the Six Months Ended June 30, 2025 (GlobeNewswire)
10:30AM	Loading…
Aug-19-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +76.87%
08:30AM	PainReform/DeepSolar Accepted into NVIDIA Connect Program (GlobeNewswire)
Aug-13-25 08:30AM	PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System (GlobeNewswire) +7.12%
Jul-10-25 08:30AM	PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio (GlobeNewswire)
May-27-25 12:12PM	Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales (PR Newswire)
May-07-25 04:30PM	PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar Platform to Optimize One of Romania's Largest Solar Projects (GlobeNewswire) -8.49%
Apr-10-25 08:30AM	PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market (GlobeNewswire) +18.13%
Apr-07-25 05:00PM	PainReform Provides Year-End Business Update (GlobeNewswire) -8.13% -8.94%
Mar-06-25 11:06AM	PainReform completes acquisition of DeepSolar (TipRanks)
Mar-05-25 11:00AM	PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics (GlobeNewswire)
Feb-18-25 08:30AM	PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity (GlobeNewswire) +31.56%
Dec-28-24 09:17AM	PainReform Faces Setback in Phase 3 Trial for PRF-110 (TipRanks)
Dec-27-24 08:30AM	PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110 (GlobeNewswire) -28.57%
Nov-20-24 08:30AM	PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial (GlobeNewswire) -25.71%
Nov-07-24 05:00PM	PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement (GlobeNewswire) +7.16%
Oct-25-24 09:25AM	PainReform cut to Hold at Maxim amid changed market dynamics (TipRanks) -8.87%
Sep-11-24 08:30AM	PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110 (GlobeNewswire) -10.38%
Sep-10-24 09:46AM	PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds (GlobeNewswire) -33.33%
Sep-09-24 12:14PM	Upcoming Stock Splits This Week (September 9 to September 13) Stay Invested (TipRanks)
Aug-21-24 08:30AM	PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy Procedures (GlobeNewswire)
Aug-20-24 08:30AM	PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study (GlobeNewswire) -15.20%
Aug-15-24 08:00AM	PainReform Provides Business Update for the Second Quarter of 2024 (GlobeNewswire)
Aug-12-24 09:00AM	PainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic Effects (GlobeNewswire)
Aug-07-24 10:00AM	PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses (GlobeNewswire)
Aug-05-24 09:00AM	PainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110 (GlobeNewswire) -12.72%
Aug-01-24 08:30AM	PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature (GlobeNewswire)
Jul-24-24 08:30AM	PainReform Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and Testing (GlobeNewswire) -6.36%
Jun-26-24 08:00AM	PainReform Completes Enrollment in the Second Part of its Phase 3 Bunionectomy Trial for PRF-110 (GlobeNewswire)
Jun-14-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -5.49%
May-31-24 04:15PM	PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
May-15-24 10:54PM	PRFX Stock Earnings: PainReform Misses EPS for Q1 2024 (InvestorPlace) -6.31%
04:05PM	PainReform Provides Business Update for the First Quarter of 2024 (GlobeNewswire)
May-08-24 08:30AM	PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com (GlobeNewswire) -6.43%
Apr-18-24 02:19PM	PainReform Announces Closing of $4 Million Public Offering (GlobeNewswire)
Apr-16-24 08:00AM	PainReform Announces Pricing of $4 Million Public Offering (GlobeNewswire) -17.42%
Apr-09-24 10:30AM	EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions (Benzinga) -13.21%
09:00AM	PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions (GlobeNewswire)
Apr-02-24 10:00AM	EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug (Benzinga)
08:30AM	PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy (GlobeNewswire)
Mar-01-24 08:00AM	PainReform Provides Year-End Business Update (GlobeNewswire) +21.42%
Jan-22-24 08:30AM	PainReform to Present at the Microcap Conference in Atlantic City (GlobeNewswire) -7.37%
Jan-03-24 08:30AM	PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief (GlobeNewswire)
Dec-26-23 06:00PM	PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds (GlobeNewswire)
Nov-15-23 04:05PM	PainReform Provides Business Update for the Third Quarter of 2023 (GlobeNewswire) -5.33%
Sep-11-23 08:30AM	PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File (GlobeNewswire)
Sep-07-23 10:00AM	PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary (GlobeNewswire) +6.37%
Sep-05-23 08:30AM	PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City (GlobeNewswire) -7.56%
Aug-10-23 04:05PM	PainReform Provides Business Update for the Second Quarter of 2023 (GlobeNewswire)
06:45AM	7 Stocks Under $10 to Buy for August (InvestorPlace)
Jul-19-23 09:00AM	PainReform Regains Compliance with Nasdaq Continued Listing Requirements (GlobeNewswire) -8.02%
Jul-14-23 02:35PM	PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement (GlobeNewswire) +40.87%
Jul-12-23 09:05AM	PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement (GlobeNewswire) -51.58%
Jul-03-23 09:01AM	Will PainReform (NASDAQ:PRFX) Spend Its Cash Wisely? (Simply Wall St.) +17.33%
Jun-15-23 08:30AM	PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st (GlobeNewswire)
Jun-07-23 04:30PM	PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire)
May-18-23 09:00AM	PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire)
May-15-23 04:45PM	PainReform Provides Business Update for the First Quarter of 2023 (GlobeNewswire)
May-02-23 08:30AM	PainReform CEO to Present at Aegis Virtual Conference on May 4th (GlobeNewswire) -6.26%
May-01-23 08:30AM	PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire) +17.02%
Apr-17-23 09:00AM	PainReform CEO to Present at the Sequire Investor Summit in Puerto Rico on April 26th (GlobeNewswire)
Mar-28-23 09:10AM	PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery (GlobeNewswire) -10.62%
Mar-16-23 08:00AM	PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy (GlobeNewswire)
Mar-14-23 08:00AM	PainReform Announces Commencement of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire) +19.86%
Feb-07-23 04:05PM	PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaqs Minimum Bid Price Requirement (GlobeNewswire) +44.72%
Nov-15-22 08:30AM	PainReform Provides Business Update for the Third Quarter of 2022 (GlobeNewswire)
Nov-08-22 08:30AM	PainReform Provides Further Update on Manufacturing of PRF-110 (GlobeNewswire)
Oct-04-22 09:00AM	PainReform Provides PRF-110 Manufacturing Update (GlobeNewswire)
Sep-01-22 08:00AM	PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +9.03%
Aug-16-22 08:05AM	PainReform Provides Business Update for the Second Quarter of 2022 (GlobeNewswire)
08:00AM	PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)

Show Previous News

PRF Technologies Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. It offers PRF-110, an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.

Executive ChairmanDr. Ehud Geller Ph.D.

Chief Financial OfficerMr. Eyal Broder

Ph.D.Dr. Sigal Aviel eMBA

Interim CEO & DirectorMr. Efraim Cohen-Arazi

Vice President of Pharmaceutical OperationsMs. Rita Keynan M.Sc.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

PRFX

PRF Technologies Ltd

Upgrade your Finviz experience

All the Features.
Half the Price.